लेखक: Robert Giffin

In recent years, the costs of new drug development have skyrocketed. The average cost of developing a new approved drug is now estimated to be $1.3 billion (Di Masi and Grabowski, 2007). At the same …

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development becaus …

Tuberculosis is one of the leading causes of death in the world today, with 4, 500 people dying from the disease every day. Many cases of TB can be cured by available antibiotics, but some TB is resi …

Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new dr …

Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new dr …

Tuberculosis is one of the leading causes of death in the world today, with 4, 500 people dying from the disease every day. Many cases of TB can be cured by available antibiotics, but some TB is resi …

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development becaus …

In recent years, the costs of new drug development have skyrocketed. The average cost of developing a new approved drug is now estimated to be $1.3 billion (Di Masi and Grabowski, 2007). At the same …